Skip to main content
Premium Trial:

Request an Annual Quote

StageZero Raising C$4.2M in Private Placement of Stocks, Warrants

This article has been updated to correct the gross proceeds from the purchase agreement. It is C$4.2 million, not C$2.4 million.

NEW YORK – StageZero Life Sciences has entered into a securities purchase agreement for the private placement of its common shares and warrants to purchase common shares for gross proceeds of approximately C$4.2 million (US$3.3 million), the company announced on Wednesday.

StageZero is issuing 9,375,002 common shares and warrants to purchase up to an aggregate of 9,375.002 common shares at C$.448 per share and associated warrant. Each warrant entitles its holder to purchase one common share at an exercise price of C$.56 per share over four years from the issuance date.

StageZero will use the placement's net proceeds to accelerate its global growth strategy and support further commercialization of its Aristotle mRNA-based multicancer test panel and its AVRT comprehensive telehealth program.

The private placement, exclusively managed by HC Wainwright, is expected to close on or about Nov. 26. The company previously raised C$2.7 million in 2019.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.